Timmerman: Biotech success demands guts

With the odds stacked against them, intrepid biotech entrepreneurs have weathered the risky nature of drug development for decades in hopes of having an unlikely success. In these troubled financial times, however, Xconomy's Luke Timmerman writes today that developers need to keep their nerve to maintain their edge in this difficult industry. Indeed, behind some of the industry's successful drugs are those who wanted to quit on the drugs during development and those who championed further testing of the treatments. Column

Suggested Articles

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.

The platform, which is in use at companies including Agios, enables researchers to simultaneously detect DNA and protein changes in single cells.